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A drug delivery system (DDS) with analgesic and antibacterial properties would be desirable for the 
local control of post-operatory pain and the prevention for surgical site infection (SSI). The objective of 
the present study was to evaluate the antinociceptive effect of the combination between dexketoprofen 
trometamol (DXT) and chlorhexidine gluconate (CHX) in the formalin pain model. Different doses of 
CHX were combined with DXT and were locally administered in rats paw simultaneously with 5% 
formalin dilution. Flinches were documented and the antinociceptive effect was calculated. The area 
under the curve of each experimental group were calculated and the % of antinociception were compared. 
The groups of CHX and DXT showed similar antinociceptive effect. The combination groups (DXT-
CHX) showed higher antinociceptive effect that the one obtained with individual molecules. Besides 
the confirmation of DXT local antinociceptive properties, CHX also showed a positive effect; and an 
additive effect when combined with DXT.
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INTRODUCTION
Pain is a complex response, caused by different 
elements that evokes the physiological, sensory and 
emotional pain process (Szallasi, 2010). Generally, is the 
consequence of local injury that affects the anatomical, 
biochemical and sensory equilibrium. When the damage 
is exposed to bacteria contamination, a dual etiology 
may trigger different pathways of the local inflammation 
(Arnstein, 2013).
Painful conditions can be controlled by the local 
application of analgesics, such as non-steroidal anti-
inflammatory drugs (NSAIDs), which inhibit cyclo-
oxigenases (COXs) activity both central and peripherally 
(Derry et al., 2017). Dexketoprofen trometamol (DXT) 
is the water soluble S(+) enantiomer of the NSAID 
ketoprofen (Mauleón et al., 1996). Previous studies 
demonstrated the local effect of ketoprofen (Derry et al., 
2015) and DXT (Isiordia-Espinoza et al., 2014; Sagir et 
al., 2013) and other studies showed analgesic efficacy 
of DXT in different post-operative conditions (Esparza-
Villalpando et al., 2016; Rodríguez, Arbós, Amaro, 
2008). The local administration of NSAIDs is desirable 
for elective interventions where the clinician can access 
directly to the lesion site. Theoretically, if the molecules 
are administered locally obtaining acceptable analgesia, 
then systemic intake can be reduced dramatically, thus 
decreasing the incidence of side-effects as well (Arnstein, 
2013; Derry et al., 2017). In the surgical context, the 
procedure itself is susceptible to complications such as 
surgical site infection (SSI), especially in areas were 
microbial flora is abundant. This complication occurs in 
up to 30% of all surgical procedures (Bruce et al., 2001). 
The use of skin antiseptics decrease the colonization 
of bacteria and therefore reduces the events of SSI (Lee 
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et al., 2013). Chlorhexidine gluconate (CHX) is a topic 
antiseptic with antibacterial and antifungical clinical 
efficacy in different conditions, it is effective against 
gram-positive and gram-negative bacteria, some viruses 
and presents good tolerability and safety profile for the 
patient (Edmiston et al., 2010).
Animal  pa in  mode ls ,  can  be  used  to  t es t 
antinociceptive effect of drug combinations by evaluating 
the previous standardize response of rodents. The formalin 
test is a pain model used to study inflammatory pain by 
injecting noxious chemical irritant (formalin) into the paw 
of rodents (Szallasi, 2010; Krzyzanowska, Avendaño, 
2012), allowing to determine not only the individual 
response of analgesic molecules; but the effect of certain 
combinations (showing either possible antagonism, 
synergism or additive effect of analgesic molecules under 
defined conditions). A drug delivery system (DDS) that 
allows analgesic and antibacterial properties would be 
desirable for the control of post-operatory pain, especially 
when the bacterial etiology is related to painful response 
(such as surgical procedures or post-surgical infections). 
Thus, the aim of the present study was to evaluate the 
antinociceptive effect of the combination of DXT and 
CHX in formalin pain model.
MATERIAL AND METHODS
Animals
Thirty six female Wistar rats (6 per group) of 6-7 
weeks of age (200-250 g), were used in the experiment. 
The animals were obtained from the Animal Center of 
the Guanajuato University and were housed on a 12 h 
light-dark cycle at 24± 2 °C, with free access to food 
and water. On the day of the experiment, animals were 
acclimatized to the laboratory conditions for at least 2 
hours before the test. All animals were used once and 
were sacrificed immediately after the test. The study 
was carried out according to the Official Mexican Norm 
NOM-062-ZOO-1999 (Technical specifications for the 
production, care, and use of laboratory animals) and 
the Guidelines on Ethical Standards for Investigation 
of Experimental Pain in Animals (Zimmermann, 1983). 
Animals were used once during the protocol and then 
sacrificed in a CO2 chamber at the end of each experiment. 
DXT (Stein Labs®, San José, Costa Rica) was dissolved 
at the moment of the experiment in des-ionized water, 
obtaining a concentration of 12 mg/mL. CHX (Sigma 
Aldrich®, EUA), 20% water solution, was dissolved in 
des-ionized water in 3 different concentrations (0.02%, 
0.3% and 2.5% respectively).
Measurement of nociceptive response
Antinociception was assessed by the formalin test. 
The rats were placed in transparent plastic cylindrical 
chambers with mirrors placed in a 45° angle to assure 
complete viewing of the injected paw. The rats were 
injected into the dorsal surface of the hind paw with 
50 μL of dilute formalin (5%) alone or mixed with the 
appropriated concentrations of formulations using a 
30-gauge needle. The rats were observed for nociceptive 
behavior immediately after formalin injection. All 
measurements were made by an independent blinded 
evaluator. Nociceptive behavior was quantified as the 
number of flinches of the injected paws in one minute 
(min) periods, every 5 min up to 60 min after injection. 
Time-courses of nociceptive response for each group were 
constructed as mean number of flinches in each time. For 
the two phases of formalin test, the areas under the curve 
(AUC) were calculated by trapezoidal method (Allison 
et al., 1995): the first phase included the measures of the 
minutes 0-15; and the second phase the minutes 15-60. 
Group-response curves for each phase were constructed 
using six animals for each group. The percentage of 
antinociception (%AN) was calculated as follow:
 
Experimental design
The animals were injected with a total solution of 
50 µL per experiment, containing fixed volumes that kept 
the following concentrations: formalin 5%, DXT 12 mg/mL 
and CHX (with different concentrations as mentioned 
before). Proportions v/v are shown in the Table I. All 
solutions were prepared freshly the day of the test and 
were put together directly in the same syringe right before 
its application.
Statistical analysis
The antinociceptive responses are presented as 
Mean±Standard Error (S.E.M.), the AUC/%AN difference 
between experimental groups was assessed by ANOVA 
with planned contrast: a) G1 vs G2, G3, G4, G5, G6; 
contrast b) G2 vs G3, G4, G5, G6; contrast c) G3 vs G4, 
G5, G6; contrast d) G4 vs G5, G6 and contrast e) G5 vs 
G6 and the assumption of normality was assessed by 
Shapiro-Wilks test. The same contrasts were performed 
to both phase 1 and phase 2. All analysis were performed 
by statistical software R ver. 3.4.0.
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RESULTS
The test for normality (Shapiro-Wilks) showed data 
distribution not different to normal (P > 0.05). The time 
course of the nociceptive response is shown on Figure 1. 
The formalin test showed two well defined phases, the 
phase 1 (1-11 minutes) and the phase 2 (21-61 minutes) 
representing tonic acute pain and inflammatory pain 
respectively. 
The %AN and the p-values of different comparisons 
are shown on the Figures 2 and 3. Control group showed 
the lower value of %AN in both phases, the group DXT 
only (G2), and the other groups not showed statistical 
difference. Additionally, the group of CHX only (G3), 
show similar antinociceptive effect to DXT only (G2). The 
group of the combination between DXT+CHX 0.02% (G4) 
showed lower antinociceptive effect than groups G5 and 
G6, but only on the phase 1. The group of CHX only (G3) 
showed lower antinociceptive effect than the combination 
groups (G4, G5 and G6), but only on the phase 2.
DISCUSSION
This work confirmed the antinociceptive effect of 
DXT when is locally administered in the formalin test, 
using the 50% effective dose of DXT previously reported 
by Isiordia et al. (2014). The local use of NSAID´S can 
provide acceptable pain relief, commonly reported in acute 
conditions. Ketoprofen is one of the molecules with this 
effect (Derry et al., 2015), supporting the logical election 
of DXT for this investigation. Moreover, this work focuses 
on the antinociceptive effect of the combination between 
DXT and CHX in the formalin model of inflammatory 
pain. The concentrations used in this study were selected 
FIGURE 1 - Time course of the nociceptive behavioral response of the experimental groups (n=6 rats each group). Each symbol 
represents the mean with S.E.M., over the 60 min post-injection observation period.
TABLE I - Description of the experimental groups
Groups µL of Formalin µL of DXT† µL of CHX‡ % of CHX
G1 (Control) 50 - - -
G2 (DXT only) 25 25 - -
G3 (CHX 0.3% only) 25 - 25 0.3
G4 (DXT + CHX 0.02%) 25 12.5 12.5 0.02
G5 (DXT + CHX 0.3%) 25 12.5 12.5 0.3
G6 (DXT + CHX 2.5%) 25 12.5 12.5 2.5
† Dexketoprofen trometamol, ‡ Chlorhexidine
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based on previously reported minimal inhibitory 
concentration (MIC) for CHX (Edmiston et al., 2010; 
Hope, Wilson, 2004), since they are considered non-
cytotoxic (Faria et al., 2007; Faria et al., 2009; Lee et al., 
2010; Li et al., 2009). As mentioned before, beyond the 
classic employments of formalin test, this research tool 
also can discard possible antagonistic reactions between 
the components of new pharmacological combinations; in 
FIGURE 3 - Antinociceptive effects (%AN) of control and experimental groups in the second phase of formalin test. Data are 
present in Mean±S.E.M. of n=6 rats for each group. The letters represent the planned contrast ANOVA: a) G1 vs G2, G3, G4, G5, 
G6; b) G2 vs G3, G4, G5, G6; c) G3 vs G4, G5, G6; d) G4 vs G5, G6 and e) G5 vs G6.
FIGURE 2 - Antinociceptive effects (%AN) of control and experimental groups in the first phase of formalin test. Data are present 
in Mean±S.E.M. of n=6 rats for each group. The letters represent the planned contrast ANOVA: a) G1 vs G2, G3, G4, G5, G6; b) 
G2 vs G3, G4, G5, G6; c) G3 vs G4, G5, G6; d) G4 vs G5, G6 and e) G5 vs G6.
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our case, it was selected as the departure point to propose 
an analgesic/antiseptic DDS.
The behavioral response showed the classical two 
phases induced by the formalin test (Gonzalez et al., 2011; 
Miranda et al., 2011; Krzyzanowska, Avendaño, 2012). 
Phase 1 results from a direct stimulation of nociceptors 
and phase 2 involves a period of sensitization during the 
inflammatory process through peripheral mechanisms (Le 
Bars, Gozariu, Cadden, 2001). The expected result was that 
the combination between both did not showed a decreased 
antinociceptive effect, conversely, the combination 
showed an increased antinociceptive effect than the drug 
alone, but these differences were not significative. 
To our knowledge, an antinociceptive effect related 
to local application of CHX has not yet been reported. 
Haraji and Rakhshan showed in a clinical trial an analgesic 
effect of the CHX gel in post-operative pain condition. As 
the authors hypothesized, the antiseptic feature of the CHX 
is possibly related to the reduction in painful inflammation 
mediators caused by bacteria (Haraji, Rakhshan, 2015). 
However, these results were inconclusive and more studies 
are needed to confirm these findings. Even when such 
conclusion may be indirectly related to the present results, 
they cannot be correlated since the nociceptive response 
of the formalin test is related to a noxious chemical 
stimulus and no to bacterial presence. In this context, the 
possible mechanism involved in the antinociceptive or 
analgesic response of the CHX should be analyze in deeper 
specialized models, including the analysis of specific 
pain pathways, expression of potential mediators or even 
the agonism/antagonism of certain receptors. Due to its 
chemical composition and ionic charge, CHX molecules 
may modulate the nervous conduction responsible of pain 
transmission, or even may contribute by blocking specific 
peripheral ionic channels. The bactericidal effect of CHX 
is a result of the binding of the CHX cationic molecules to 
negatively charged bacterial cell walls and extramicrobial 
complexes (McDonnell, Russell, 1999). A possible reason 
of the antinociceptive effect observed may involve the 
positively charged CHX interacting with the membranes of 
the peripheral nerve endings, thus creating the modulation 
of the action potential evoked by the formalin. However, 
any of these hypotheses must be meticulously analyzed 
in new experiments.
The surgical procedures involve wounds that will 
heal by primary or secondary intention. In the procedures 
involving “clean” cavities, the surgical infection 
prevalence is around 3% to 5%; but, when the procedures 
involve infected sites, dirty or necrotic tissue; the surgical 
infections increase up to 10% to 30% (White, 2009). The 
oral cavity is considered clean/contaminated and the risk 
for surgical infection is latent. The wound infection results 
from the dynamic interactions between the presence of 
pathogens and the susceptibility of the host. The pathways 
of the surgical infection are complex; however, the most 
common signs are erythema, pain, local temperature and 
swelling (Gardner, Frantz, Doebbeling, 2001).
The presence of pain is part of the local inflammatory 
reaction, and thus, it will be expected to decrease at the 
same rhythm that the etiology is controlled and the 
inflammation is auto-limited. To increase the quality of 
life of the patients, analgesic/antiseptic DDS will play a 
dual role, by modulating the normal painful response of 
inflammation while favoring the local septic ethology. 
When pain is poorly controlled, a pain-related infection 
would reduce the immune response to infection. Therefore, 
the control of pain is as important as the treatment of 
infection itself (White, 2009). The use of CHX could 
provide an extra analgesic effect in combination with 
DXT and at the same time covering the antimicrobial role 
to prevent SSI. 
Since our results not only demonstrated that the 
presence of CHX didn´t affect the local antinociceptive 
effect of DXT (confirmed in our results), but the molecule 
itself showed to have antinociceptive capacity, and the 
presence of an additive effect between both molecules; 
a new favorable result must be concluded. Further 
efforts will be addressed not only to fully understand this 
hypothesis and the mechanisms involved, but to include 
new experiments analyzing decreasing combinatory doses 
in order to perform an isobolographic analysis (Tallarida, 
2001), looking for possible pharmacological synergism.
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